<?xml version='1.0' encoding='utf-8'?>
<document id="27225997"><sentence text="Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation."><entity charOffset="79-90" id="DDI-PubMed.27225997.s1.e0" text="Cobimetinib" /></sentence><sentence text="Cobimetinib is eliminated mainly through cytochrome P450 (CYP) 3A4-mediated hepatic metabolism in humans"><entity charOffset="0-11" id="DDI-PubMed.27225997.s2.e0" text="Cobimetinib" /></sentence><sentence text=" A clinical drug-drug interaction (DDI) study with the potent CYP3A4 inhibitor itraconazole resulted in an approximately sevenfold increase in cobimetinib exposure"><entity charOffset="79-91" id="DDI-PubMed.27225997.s3.e0" text="itraconazole" /><entity charOffset="143-154" id="DDI-PubMed.27225997.s3.e1" text="cobimetinib" /><pair ddi="false" e1="DDI-PubMed.27225997.s3.e0" e2="DDI-PubMed.27225997.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27225997.s3.e0" e2="DDI-PubMed.27225997.s3.e1" /></sentence><sentence text=" The DDI risk for cobimetinib with other CYP3A4 inhibitors and inducers needs to be assessed in order to provide dosing instructions"><entity charOffset="18-29" id="DDI-PubMed.27225997.s4.e0" text="cobimetinib" /></sentence><sentence text="" /><sentence text="A physiologically based pharmacokinetic (PBPK) model was developed for cobimetinib using in vitro data"><entity charOffset="71-82" id="DDI-PubMed.27225997.s6.e0" text="cobimetinib" /></sentence><sentence text=" It was then optimized and verified using clinical pharmacokinetic data and itraconazole-cobimetinib DDI data"><entity charOffset="76-88" id="DDI-PubMed.27225997.s7.e0" text="itraconazole" /></sentence><sentence text=" The contribution of CYP3A4 to the clearance of cobimetinib in humans was confirmed using sensitivity analysis in a retrospective simulation of itraconazole-cobimetinib DDI data"><entity charOffset="48-59" id="DDI-PubMed.27225997.s8.e0" text="cobimetinib" /><entity charOffset="144-156" id="DDI-PubMed.27225997.s8.e1" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.27225997.s8.e0" e2="DDI-PubMed.27225997.s8.e0" /><pair ddi="false" e1="DDI-PubMed.27225997.s8.e0" e2="DDI-PubMed.27225997.s8.e1" /></sentence><sentence text=" The verified PBPK model was then used to predict the effect of other CYP3A4 inhibitors and inducers on cobimetinib pharmacokinetics"><entity charOffset="104-115" id="DDI-PubMed.27225997.s9.e0" text="cobimetinib" /></sentence><sentence text="" /><sentence text="The PBPK model described cobimetinib pharmacokinetic profiles after both intravenous and oral administration of cobimetinib well and accurately simulated the itraconazole-cobimetinib DDI"><entity charOffset="25-36" id="DDI-PubMed.27225997.s11.e0" text="cobimetinib" /><entity charOffset="112-123" id="DDI-PubMed.27225997.s11.e1" text="cobimetinib" /><entity charOffset="158-170" id="DDI-PubMed.27225997.s11.e2" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.27225997.s11.e0" e2="DDI-PubMed.27225997.s11.e0" /><pair ddi="false" e1="DDI-PubMed.27225997.s11.e0" e2="DDI-PubMed.27225997.s11.e1" /><pair ddi="false" e1="DDI-PubMed.27225997.s11.e0" e2="DDI-PubMed.27225997.s11.e2" /><pair ddi="false" e1="DDI-PubMed.27225997.s11.e1" e2="DDI-PubMed.27225997.s11.e1" /><pair ddi="false" e1="DDI-PubMed.27225997.s11.e1" e2="DDI-PubMed.27225997.s11.e2" /></sentence><sentence text=" Sensitivity analysis suggested that CYP3A4 contributes ~78 % of the total clearance of cobimetinib"><entity charOffset="88-99" id="DDI-PubMed.27225997.s12.e0" text="cobimetinib" /></sentence><sentence text=" The PBPK model predicted no change in cobimetinib exposure (area under the plasma concentration-time curve, AUC) with the weak CYP3A inhibitor fluvoxamine and a three to fourfold increase with the moderate CYP3A inhibitors, erythromycin and diltiazem"><entity charOffset="39-50" id="DDI-PubMed.27225997.s13.e0" text="cobimetinib" /><entity charOffset="144-155" id="DDI-PubMed.27225997.s13.e1" text="fluvoxamine" /><entity charOffset="225-237" id="DDI-PubMed.27225997.s13.e2" text="erythromycin" /><pair ddi="false" e1="DDI-PubMed.27225997.s13.e0" e2="DDI-PubMed.27225997.s13.e0" /><pair ddi="false" e1="DDI-PubMed.27225997.s13.e0" e2="DDI-PubMed.27225997.s13.e1" /><pair ddi="false" e1="DDI-PubMed.27225997.s13.e0" e2="DDI-PubMed.27225997.s13.e2" /><pair ddi="false" e1="DDI-PubMed.27225997.s13.e1" e2="DDI-PubMed.27225997.s13.e1" /><pair ddi="false" e1="DDI-PubMed.27225997.s13.e1" e2="DDI-PubMed.27225997.s13.e2" /></sentence><sentence text=" Similarly, cobimetinib exposure in the presence of strong (rifampicin) and moderate (efavirenz) CYP3A inducers was predicted to decrease by 83 and 72 %, respectively"><entity charOffset="12-23" id="DDI-PubMed.27225997.s14.e0" text="cobimetinib" /><entity charOffset="60-70" id="DDI-PubMed.27225997.s14.e1" text="rifampicin" /><entity charOffset="86-95" id="DDI-PubMed.27225997.s14.e2" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.27225997.s14.e0" e2="DDI-PubMed.27225997.s14.e0" /><pair ddi="false" e1="DDI-PubMed.27225997.s14.e0" e2="DDI-PubMed.27225997.s14.e1" /><pair ddi="false" e1="DDI-PubMed.27225997.s14.e0" e2="DDI-PubMed.27225997.s14.e2" /><pair ddi="false" e1="DDI-PubMed.27225997.s14.e1" e2="DDI-PubMed.27225997.s14.e1" /><pair ddi="false" e1="DDI-PubMed.27225997.s14.e1" e2="DDI-PubMed.27225997.s14.e2" /></sentence><sentence text="" /><sentence text="This study demonstrates the value of using PBPK simulation to assess the clinical DDI risk inorder to provide dosing instructions with other CYP3A4 perpetrators" /><sentence text="" /></document>